Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$133.41 +0.0%	$133.49	$99.71 ▼ $141.23	$232.02B	0.73	6.14 million shs	4.61 million shs
LLY Eli Lilly and Company	$787.00 +1.2%	$767.12	$677.09 ▼ $972.53	$737.02B	0.4	3.65 million shs	2.70 million shs
MRK Merck & Co., Inc.	$83.74 +2.9%	$79.06	$73.31 ▼ $129.93	$204.32B	0.39	13.32 million shs	18.39 million shs
NVO Novo Nordisk A/S	$69.80 +0.2%	$70.25	$57.00 ▼ $143.49	$310.94B	0.64	7.26 million shs	5.37 million shs
PFE Pfizer	$25.56 -0.2%	$23.82	$20.92 ▼ $31.54	$145.66B	0.58	41.64 million shs	38.34 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+0.04%	-0.50%	0.00%	+7.28%	+31.26%
LLY Eli Lilly and Company	+1.17%	+1.03%	+1.73%	+9.33%	-15.68%
MRK Merck & Co., Inc.	+2.94%	+1.68%	+5.60%	+8.16%	-33.58%
NVO Novo Nordisk A/S	+0.24%	-0.01%	-7.49%	+14.21%	-50.29%
PFE Pfizer	-0.20%	+0.95%	+6.65%	+18.51%	-7.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9141 of 5 stars	2.4	3.0	4.2	4.5	3.4	2.5	2.5
LLY Eli Lilly and Company	4.9808 of 5 stars	4.4	4.0	3.3	4.0	3.0	1.7	1.9
MRK Merck & Co., Inc.	4.9985 of 5 stars	3.2	3.0	5.0	4.2	3.5	2.5	3.8
NVO Novo Nordisk A/S	4.688 of 5 stars	4.1	5.0	2.5	0.0	2.4	0.0	3.1
PFE Pfizer	4.9739 of 5 stars	3.2	3.0	4.2	4.5	3.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.76	Moderate Buy	$143.11	7.27% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	28.54% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	30.39% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	60.46% Upside
PFE Pfizer	2.45	Hold	$28.55	11.70% Upside

Current Analyst Ratings Breakdown

Latest PFE, LLY, NVO, ABT, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ABT Abbott Laboratories	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$140.00 ➝ $145.00
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.53	$6.58 per share	20.26	$27.62 per share	4.83
LLY Eli Lilly and Company	$45.04B	16.56	$14.41 per share	54.63	$15.03 per share	52.36
MRK Merck & Co., Inc.	$64.17B	3.28	$9.74 per share	8.60	$18.33 per share	4.57
NVO Novo Nordisk A/S	$303.14B	1.03	$3.91 per share	17.85	$4.66 per share	14.98
PFE Pfizer	$63.63B	2.28	$4.35 per share	5.87	$15.62 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.71	17.30	23.28	2.53	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	64.04	25.29	1.14	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	12.19	8.46	0.84	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.65	14.98	1.36	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.52	8.44	0.93	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest PFE, LLY, NVO, ABT, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.56	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.89	N/A	N/A	N/A	$77.51 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.77%	N/A	30.61%	54 Years
LLY Eli Lilly and Company	$6.00	0.76%	N/A	48.82%	11 Years
MRK Merck & Co., Inc.	$3.24	3.87%	N/A	47.16%	14 Years
NVO Novo Nordisk A/S	$1.63	2.34%	N/A	48.22%	N/A
PFE Pfizer	$1.72	6.73%	N/A	124.64%	16 Years

Latest PFE, LLY, NVO, ABT, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
LLY Eli Lilly and Company	2.18	1.37	1.06
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVO Novo Nordisk A/S	0.70	0.74	0.56
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
LLY Eli Lilly and Company	0.13%
MRK Merck & Co., Inc.	0.13%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, LLY, NVO, ABT, and MRK Headlines

Recent News About These Companies

Pfizer Inc. (NYSE:PFE) Shares Sold by Lbp Am Sa

1 hour ago | marketbeat.com

Axxcess Wealth Management LLC Sells 31,881 Shares of Pfizer Inc. (NYSE:PFE)

1 hour ago | marketbeat.com

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

1 hour ago | businesswire.com

European Commission president Ursula von der Leyen delivers her speech during a statement on the pr…

EU official Ursula von der Leyen comfortably survives a confidence vote

...

2 hours ago | marketbeat.com

Brown Advisory Inc. Sells 117,326 Shares of Pfizer Inc. (NYSE:PFE)

3 hours ago | marketbeat.com

Pfizer Earnings Preview: What to Expect

July 9 at 6:59 PM | msn.com